1. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
- Author
-
Aass C, Norheim I, Eriksen EF, Børnick EC, Thorsby PM, and Pepaj M
- Subjects
- Adult, Aged, Diagnosis, Differential, Enzyme-Linked Immunosorbent Assay, Female, Glycoproteins analysis, Graves Disease diagnosis, Graves Ophthalmopathy diagnosis, Humans, Male, Middle Aged, Muramidase analysis, ROC Curve, Seminal Plasma Proteins analysis, Severity of Illness Index, Young Adult, Zn-Alpha-2-Glycoprotein, Biomarkers analysis, Eye Proteins analysis, Graves Disease metabolism, Graves Ophthalmopathy metabolism, Tears metabolism
- Abstract
Background: Graves' orbitopathy (GO) is an autoimmune inflammatory ocular complication and one of the most frequent manifestations of Graves' disease (GD). Clinical judgment of GO is subjective sometimes leading to clinical and therapeutic challenges. Better tools to diagnose this severe complication are warranted., Patients and Methods: The aim of the present study was to evaluate tear levels of LYZ, LACRT and AZGP1 in GD patients with or without GO, as possible biomarkers for GO. Tear samples were collected from GD patients with moderate-to-severe GO (n = 21) and no clinical signs of GO (n = 21). Additionally, 18 GD patients with mild GO and 9 patients without GO were included in a further part of the study., Results: Tear levels of LYZ (p < 0.001), LACRT (p = 0.004) and AZGP1 (p = 0.001) were significantly elevated in GD patients with moderate-to-severe GO compared to GD patients without GO. The discriminatory power of the three biomarkers, combined in a panel was confirmed by ROC plot analysis, with an AUC value of 0.93 (sensitivity of 95%; specificity of 80%). Since LYZ showed the best performance in discriminating between GD patients with (moderate-to-severe) and without GO (in combination with limited sample volume available), LYZ levels were also measured in tears from GD patients with mild GO and without GO. Significantly higher levels of LYZ were measured in GD patients with mild GO compared to those without GO (p = 0.003)., Conclusions: We have established a novel three-protein biomarker panel that is able to discriminate between GD patients with and without GO, which might aid in diagnostic evaluation of GO as well as an indicator for disease activity.
- Published
- 2017
- Full Text
- View/download PDF